Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth

Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellavia, Daniele, Raimondo, Stefania, Calabrese, Giovanna, Forte, Stefano, Cristaldi, Marta, Patinella, Agostina, Memeo, Lorenzo, Manno, Mauro, Raccosta, Samuele, Diana, Patrizia, Cirrincione, Girolamo, Giavaresi, Gianluca, Monteleone, Francesca, Fontana, Simona, De Leo, Giacomo, Alessandro, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399597/
https://www.ncbi.nlm.nih.gov/pubmed/28435469
http://dx.doi.org/10.7150/thno.17092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399597/
https://www.ncbi.nlm.nih.gov/pubmed/28435469
http://dx.doi.org/10.7150/thno.17092

Ejemplares similares